medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2012, Number 05-06

<< Back

Medicina & Laboratorio 2012; 18 (05-06)

Utilidad de la presepsina en el diagnóstico y evaluación de la severidad de la sepsis
Evaluación de la capacidad funcional del colesterol de alta densidad en la aterosclerosis

Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S

Language: Spanish
References: 13
Page: 289-293
PDF size: 285.06 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Vincent JL. Clinical sepsis and septic shock- definition, diagnosis and management principles. Langenbecks Arch Surg 2008; 393: 817-824.

  2. Dreiher J, Almog Y, Sprung CL, Codish S, Klein M, Einav S, et al. Temporal trends in patient characteristics and survival of intensive care admissions with sepsis: A multicenter analysis. Crit Care Med. 2012; 40: 855-860.

  3. Rodríguez F, Barrera L, De La Rosa G, Dennis R, Dueñas C, Granados M, et al. The epidemiology of sepsis in Colombia: a prospective multicenter cohort study in ten university hospitals. Crit Care Med 2011; 39: 1675-1682.

  4. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Survivng Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34:17-60.

  5. Chan YL, Tseng CP, Tsay PK, Chang SS, Chiu TF, Chen JC. Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit Care. 2004; 8: 12-20.

  6. Giamarellos-Bourboulis EJ, Giannopoulou P, Grecka P, Voros D, Mandragos K, Giamarellou H. Should procalcitonin be introduced in the diagnostic criteria for the systemic inflammatory response syndrome and sepsis? J Crit Care 2004; 19: 152–157

  7. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Endo S,et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005; 11: 234–238.

  8. Okamura Y, Yokoi H. Development of a pointof- care assay system for measurement of presepsin (sCD14- ST) Clinica Chimica Acta, 2011 412: 2157- 2161

  9. Low H, Hoang A, Sviridov D. Cholesterol efflux assay. J Vis Exp 2012; (61): e3810.

  10. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006; 113: 2548-2555.

  11. De la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010; 30: 796-801.

  12. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23: 712-719.

  13. Thorngate FE, Yancey PG, Kellner-Weibel G, Rudel LL, Rothblat GH, Williams DL. Testing the role of apoA-I, HDL, and cholesterol efflux in the atheroprotective action of low-level apoE expression. J Lipid Res 2003; 44: 2331-2338.




2020     |     www.medigraphic.com